Get started
Author

Ana Inés Varela

Observed names: A. I. Varela, Ana I. Varela, Ana Ines Varela, Ana Varela, Varela, Ana, Varela, Ana Inés
Observed institution: Hospital Ramos Mejía
ORCID: 0000-0002-4772-3789
Observed ORCID: 0000-0002-4772-3789
OpenAlex ID: A5003113496
Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
2021 · Carolina Pavlovsky, Virginia Abello Polo, et al. · Blood Advances · 44
High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis
2023 · Geraldine De Luca, Paola R. Lev, et al. · Frontiers in Immunology · 18
PDF
PET ‐adapted therapy after three cycles of ABVD for all stages of Hodgkin lymphoma: results of the GATLA LH ‐05 trial
2019 · Astrid Pavlovsky, Isolda Fernandez, et al. · British Journal of Haematology · 15
In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
2023 · María Belén Sanchez, Bianca Vasconcelos Cordoba, et al. · Frontiers in Immunology · 13
PDF
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
2023 · Carolina Pavlovsky, Bianca Vasconcelos Cordoba, et al. · Journal of Hematology & Oncology · 13
PDF
miRNome profiling of LSC-enriched CD34+CD38−CD26+ fraction in Ph+ CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool
2021 · María Sol Ruiz, María Belén Sánchez, et al. · Frontiers in Pharmacology · 12
PDF
Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis
2023 · María José Mela Osorio, Beatriz Moiraghi, et al. · Clinical Lymphoma Myeloma & Leukemia · 9
Results from the 208-Week (4-Year) Follow-up of RESPONSE Trial, a Phase 3 Study Comparing Ruxolitinib (Rux) with Best Available Therapy (BAT) for the Treatment of Polycythemia Vera (PV)
2017 · Jean‐Jacques Kiladjian, Srđan Verstovšek, et al. · Blood · 8
P715: Multicenter Observational Study of Ponatinib in Cml Patients in Argentina. Real-world Experience.
2022 · M. J. Mela Osorio, M. V. Osycka, et al. · HemaSphere · 4
Challenges in Chronic Myeloid Leukemia Management in South America
2021 · Katia B. Pagnano, Ana Ines Varela, et al. · Current Hematologic Malignancy Reports · 4
The Influence of the COVID-19 Pandemic in NK Cell Subpopulations from CML Patients Enrolled in the Argentina Stop Trial
2025 · María Belén Sanchez, Bianca Vasconcelos Cordoba, et al. · Cells · 2
PDF
High Level of Successful TKI Discontinuation in Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of AST-Argentina Stop Trial
2020 · Carolina Pavlovsky, Ana Ines Varela, et al. · Blood · 2
Ruxolitinib In Myelofibrosis (MF) Patients Through Compassionate Use Program (CUP). Argentinian Experience
2013 · Mauricio A Alzate, María J Mela Osorio, et al. · Blood · 2
Long-Term Follow-up of the AST Trial of Treatment-Free Remission in Chronic Myeloid Leukemia Patients
2023 · Ricardo K Tannuri, Beatriz Moiraghi, et al. · Blood · 1
Economic Impact Analysis of Treatment-Free Remission in Chronic Myeloid Leukemia Patients with Sustained Deep Molecular Response in the AST-2018 Trial
2022 · Ricardo Khalil Khalil Tannuri, Beatriz Moiraghi, et al. · Blood · 1
The Prognostic Impact of HMGCLL1 Gene Variant on Treatment Outcomes in Chronic Myeloid Leukemia (CML) Patients: Adverse Impact on the Response, Failure, and Progression with Imatinib Which Can be Abrogated By the Use of 2nd Generation Tyrosine Kinase Inhibitor (TKI) Upfront Therapy
2022 · Maria Agustina Perusini, Taehyung Simon Kim, et al. · Blood · 1
Real World Efficacy Evaluation of Branded and Copy Imatinib in Chronic Myeloid Leukemia: A Retrospective Multicentric Study from Argentina
2020 · Ana Ines Varela, Georgina Bendek, et al. · Blood · 1
Daily Practice Experience in Ponatinib Treatment of Chronic Myeloid Leukemia (CML) Patients Resistant to Other Tyrosin Kynase Inhibitors (TKIs) in Argentina
2015 · Ana Inés Varela, Romina Laura Penalba, et al. · Blood · 1
Identification of Predictive Biomarkers Based on Cytokine Profiles for Molecular Relapse After Treatment-Free Remission in Chronic Myeloid Leukemia Patients
2026 · Bianca Vasconcelos Cordoba, Carolina Pavlovsky, et al. · Cells
PDF
The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
2026 · Maria Agustina Perusini, Katia Pagnano, et al. · Leukemia
Integrating cytokine profiles with clinical and molecular biomarkers to predict molecular relapse after TKI discontinuation in CML patients
2025 · Carolina Pavlovsky, Bianca Vasconcelos Cordoba, et al. · Blood
Clinical practice recommendations for myelofibrosis management in Latin America from an expert consensus group
2025 · Renato Tavares, Virginia Abello Polo, et al. · Blood Global Hematology
Assessing Molecular Relapse-Free Survival in Latin American Chronic Myeloid Leukemia Patients Undergoing TKI Dose Reduction
2024 · Melina Gisel Luft, Ricardo Khalil Tannuri, et al. · Blood
Final Report: Somatic Mutations and HMGCLL1 Haplotype Are Not Associated with Molecular Relapse-Free Survival in Patients with Chronic Myeloid Leukemia Who Attempt Treatment-Free Remission
2023 · Maria Agustina Perusini, Katia Pagnano, et al. · Blood
Somatic Mutations Are Frequently Detected in CML Patients before Treatment-Free Remission (TFR) Attempt with Tyrosine Kinase Inhibitor (TKI) Discontinuation but with Uncertain Predictive Value for Tfr Failure
2022 · Maria Agustina Perusini, Katia B Pagnano, et al. · Blood
Works count: 36
Citation count: 151
H-index: 8
I10-index: 6
Year
Topic
Type